/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, June 3, 2026 /CNW/ - Principal Technologies Inc. (TSXV: PTEC) (FWB:...
Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.
New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
The Expansion, which has created more than 70 new positions, is Driven by Growing Interest in the Biogas, Aerospace and Marine Industries Air Products...
BUFFALO, N.Y., June 3, 2026 /PRNewswire/ -- What does homeowners insurance really protect, and how can homeowners avoid costly surprises? That question is answered...
LAMESA, Texas, June 3, 2026 /PRNewswire/ -- The article explores how personalized care and lifestyle-focused evaluations support long-term overall wellness.
...
Brain Navi Biotechnology Achieves Key Regulatory Milestone Following Recognition at the 22nd National Innovation AwardZHUBEI, June 3, 2026 /PRNewswire/ -- Brain Navi Biotechnology announced that...
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...